Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
BCD (Bendamustine, carboplatin and dexamethasone)chemotherapy regimen is proposed as the
salvage treatment for relapsed or refractory PTCLs in this study protocol, which would be
expected to show more promising clinical outcomes than that of bendamustine single therapy.
Platinum combination with bendamustine is a theoretically ideal salvage regimen for the
patients of PTCLs because these both agents are highly effective drugs in lymphoma treatment
and have rare cross-resistance. Carboplatin was selected as a platinum agent for combination
with bendamustine, which is a second generation platinum agent and has a less neurotoxicity
than that of cisplatin, considering use for previously treated patients with vinc alkaloid
agents.
In a prior phase I study of carboplatin in combination with bendamustine for previously
untreated small cell lung cancer patients, the recommended dose for phase II studies was
bendamustine 100 mg/m2 on day 1 and 2, carboplatin AUC 5 on day 1, respectively [16]. In
consideration of previously treated subjects, however, the dose of bendamustine was decided
on 80mg/m2 in this study protocol with concerning about the toxicities, especially to severe
cytopenia.
Dexamethasone is one of the corticosteroids using a key drug for lymphoid malignancy and has
a strong antiemetic effect. Therefore, dexamethasone could enhance the therapeutic efficacy
and antiemetic effect, using with bendamustine and carboplatin.